NASDAQ:LKFT Lakefront Biotherapeutics American Depositary Shares (LKFT) Stock Price, News & Analysis $30.72 +0.53 (+1.76%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Lakefront Biotherapeutics American Depositary Shares Stock (NASDAQ:LKFT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get LKFT alerts:Sign Up Key Stats Today's Range$30.66▼$32.4150-Day Range$26.08▼$30.7252-Week Range$25.68▼$37.78Volume635,291 shsAverage Volume271,003 shsMarket Capitalization$2.02 billionP/E RatioN/ADividend YieldN/APrice Target$37.00Consensus RatingHold Company Overview Lakefront is a clinical-stage biotechnology company developing therapies in immunology and inflammation. Its clinical-stage portfolio includes lead asset gamgertamig, a BCMAxCD3 T-cell engager being developed for the treatment of autoimmune diseases. The company identifies, acquires, and advances therapeutic assets through business development and clinical development activities. Lakefront evaluates opportunities for portfolio expansion based on their scientific, clinical, and commercial potential. Lakefront focuses on developing medicines for diseases with unmet medical needs and advancing its product candidates through clinical development. Read More Lakefront Biotherapeutics American Depositary Shares Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks38th Percentile Overall ScoreLKFT MarketRank™: Lakefront Biotherapeutics American Depositary Shares scored higher than 38% of companies evaluated by MarketBeat, and ranked 838th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingModerate Buy Consensus RatingLakefront Biotherapeutics American Depositary Shares has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on 1 strong buy rating, 3 buy ratings, 5 hold ratings, and no sell ratings.Upside PotentialLakefront Biotherapeutics American Depositary Shares has a consensus price target of $37.00, representing about 20.4% upside from its current price of $30.72.Amount of Analyst CoverageLakefront Biotherapeutics American Depositary Shares has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Lakefront Biotherapeutics American Depositary Shares' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Lakefront Biotherapeutics American Depositary Shares are expected to decrease in the coming year, from ($1.27) to ($1.80) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lakefront Biotherapeutics American Depositary Shares is -21.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lakefront Biotherapeutics American Depositary Shares is -21.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLakefront Biotherapeutics American Depositary Shares has a P/B Ratio of 0.65. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.15% of the float of Lakefront Biotherapeutics American Depositary Shares has been sold short.Short Interest Ratio / Days to CoverLakefront Biotherapeutics American Depositary Shares has a short interest ratio ("days to cover") of 14, which indicates bearish sentiment.Change versus previous monthShort interest in Lakefront Biotherapeutics American Depositary Shares has recently increased by 10.84%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLakefront Biotherapeutics American Depositary Shares does not currently pay a dividend.Dividend GrowthLakefront Biotherapeutics American Depositary Shares does not have a long track record of dividend growth. News and Social Media2.1 / 5News Sentiment0.39 News SentimentLakefront Biotherapeutics American Depositary Shares has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Lakefront Biotherapeutics American Depositary Shares this week, compared to 3 articles on an average week. Company Ownership0.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Lakefront Biotherapeutics American Depositary Shares insiders have not sold or bought any company stock.Percentage Held by Insiders2.91% of the stock of Lakefront Biotherapeutics American Depositary Shares is held by insiders.Percentage Held by Institutions32.46% of the stock of Lakefront Biotherapeutics American Depositary Shares is held by institutions.Read more about Lakefront Biotherapeutics American Depositary Shares' insider trading history. Receive LKFT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lakefront Biotherapeutics American Depositary Shares and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LKFT Stock News HeadlinesLakefront Biotherapeutics' Gamgertamig Has Meaningful Opportunity in Rare Autoimmune Diseases, RBC Says3 hours ago | marketscreener.comMRBC Upgrades Lakefront Biotherapeutics to Outperform From Sector Perform, Adds Speculative Risk, Raises Price Target to $45 From $26September 23 at 10:32 AM | marketscreener.comMLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.September 23 at 1:00 AM | InvestorPlace (Ad)Acquisition of Own SharesSeptember 22 at 4:01 PM | globenewswire.comLakefront Biotherapeutics NV (LKFT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 17, 2026 | seekingalpha.comAcquisition of Own SharesSeptember 15, 2026 | globenewswire.comLakefront Biotherapeutics: A Cash Discount With A More Credible Path To ValueSeptember 15, 2026 | seekingalpha.comAcquisition of Own SharesSeptember 8, 2026 | globenewswire.comSee More Headlines LKFT Stock Analysis - Frequently Asked Questions How have LKFT shares performed this year? Lakefront Biotherapeutics American Depositary Shares' stock was trading at $32.70 at the beginning of 2026. Since then, LKFT shares have decreased by 6.1% and is now trading at $30.72. How were Lakefront Biotherapeutics American Depositary Shares' earnings last quarter? Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) released its quarterly earnings data on Monday, August, 10th. The biotechnology company reported $0.04 EPS for the quarter, topping the consensus estimate of ($0.97) by $1.01. The biotechnology company earned $15.47 million during the quarter, compared to the consensus estimate of $7.29 million. How do I buy shares of Lakefront Biotherapeutics American Depositary Shares? Shares of LKFT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Lakefront Biotherapeutics American Depositary Shares own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lakefront Biotherapeutics American Depositary Shares investors own include American Water Works (AWK), Humana (HUM), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AUO (AUOTY). Company Calendar Last Earnings8/10/2026Today9/23/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (6m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 LKFT's financial health is in the Red zone, according to TradeSmith. LKFT has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:LKFT Previous SymbolNASDAQ:GLPG CIK1421876 Webwww.glpg.com Phone(321) 534-2900Fax321-534-2901Employees1,310Year Founded1999Price Target and Rating Average Price Target for Lakefront Biotherapeutics American Depositary Shares$37.00 High Price Target$45.00 Low Price Target$26.00 Potential Upside/Downside+20.4%Consensus RatingModerate Buy Rating Score (0-4)2.56 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio32.84 Quick Ratio32.72 Sales & Book Value Annual Sales$990.57 million Price / Sales2.04 Cash Flow$0.74 per share Price / Cash Flow41.58 Book Value$47.57 per share Price / Book0.65Miscellaneous Outstanding Shares65,897,000Free Float63,979,000Market Cap$2.02 billion OptionableOptionable Beta0.28 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:LKFT) was last updated on 9/23/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lakefront Biotherapeutics American Depositary Shares Please log in to your account or sign up in order to add this asset to your watchlist. Share Lakefront Biotherapeutics American Depositary Shares With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LKFT Stock Alerts